Under one in 10 patients who could benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it releases its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
According to projections, more than two billion are projected to be obese by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major hurdles to universal access to the treatments that can help people shift substantial body mass, notes the body.
Skinny Jab Shortage
Despite the present most optimistic case, the production of these medications might only reach approximately 100 million people – fewer than 10% of eligible patients, per the WHO.
The advice urges nations and manufacturers to widen availability, via approaches such as voluntary licensing.
The intellectual property rights on a key compound – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Operate
These medications replicate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so users consume fewer calories.
Individuals typically begin shedding pounds within a few weeks of starting on the regular doses.
Evidence indicates people may regain a significant portion within a year of discontinuing the medication, as their normal appetite return.
Being carrying excess weight elevates your chance for developing health problems, like diabetes, heart disease, brain attack, and some cancers.
Obesity impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the health agency.
